Home
International Pharmaceutical 3D printing Initiative (Pharma3DPI)
Patient-centric medicines
About Pharma3DPI
The International Pharmaceutical 3D Printing Initiative (Pharma3DPI) is a consortium dedicated to advancing the utilisation of 3D printing in the pharmaceutical field to improve the accessibility and advancement of patient-centric care. The consortium was founded in 2023 to help foster international and cross-organisation collaborations, propagate scientific information and discuss ideas.
Members come from around the world, being based in academia, healthcare, the pharmaceutical industry, and regulatory agencies such as the US Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA).
The initiative provides critical support in the form of expertise, events and resources to address challenges and explore emerging technologies stemming from academic research. By bringing together diverse stakeholders in the pharmaceutical sector, Pharma3DPI actively contributes to the evolution of personalised medicine and its potential benefits for patients worldwide.
Members come from around the world, being based in academia, healthcare, the pharmaceutical industry, and regulatory agencies such as the US Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA).
The initiative provides critical support in the form of expertise, events and resources to address challenges and explore emerging technologies stemming from academic research. By bringing together diverse stakeholders in the pharmaceutical sector, Pharma3DPI actively contributes to the evolution of personalised medicine and its potential benefits for patients worldwide.
Mission
- Lead and promote the innovative application of 3D printing technology in the pharmaceutical industry.
- Facilitate collaboration among stakeholders to harness 3D printing's potential for creating personalised medicines.
- Expedite the development of safer and more effective pharmaceuticals that cater to individual patient needs and preferences.
Objectives
- Foster cross-sector collaboration: Bring together academia, healthcare providers, pharmaceutical companies, and regulatory agencies to work together on 3D printing solutions.
- Drive innovation: Encourage the development and adoption of cutting-edge 3D printing technologies to improve patient well-being by tailoring pharmaceuticals.
- Ensure safety and efficacy: Discuss and promote industry standards and regulatory guidelines for the safe and effective use of 3D printed medicines.
Facts
- Non profit organisation.
- Established in London in 2023.
- Members from academia, industry, hospitals and regulatory agencies dedicated to fulfilling its mission.
- Membership open to anyone interested in 3D printing pharmaceuticals.
- 5 Workstreams.
- Annual Conferences.
